<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Czech and Slovak Ophthalmology</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">284</article-id>
      <article-id pub-id-type="doi">10.31348/2023/20</article-id>
      <article-categories>
        <subj-group>
          <subject>Case report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Giant Prolactinoma. A Case Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Anwarzai Šulavíková</surname>
            <given-names>Zuzana</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4213-9479</contrib-id>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Krásnik</surname>
            <given-names>Vladimír</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date date-type="pub" publication-format="electronic">
        <day>20</day>
        <month>6</month>
        <year>2023</year>
      </pub-date>
      <issue>3</issue>
      <elocation-id>5</elocation-id>
      <abstract>
        <p>Aim: Prolactinoma is a pituitary adenoma that secretes prolactin. Approximately 40% of all pituitary adenomas are prolactinomas. According to size, they are divided into micro, macro and giant prolactinomas. In women, prolactinomas cause irregularities of the menstrual cycle such as amenorrhea, galactorrhea, weight gain, in both sexes they cause sterility, hypogonadism, decreased libido and depression. In macroadenomas, symptoms due to the compression of the surrounding structures are also manifested, such as headache, vomiting, lower chiasmatic syndrome and ophthalmoplegia. Loss of the visual field due to compression of the optic chiasm is caused by a tumor larger than 10–15 mm with suprasellar spreading, which breaks through the diaphragma sellae. Giant prolactinomas are larger than 40 mm and make up 1–5% of all prolactinomas. Case report: In this article I present the case of a 38-year-old woman from Ukraine with advanced chiasmatic syndrome caused by a giant prolactinoma. The tumor is infiltrating the left cavernous sinus, causing left-sided amaurosis and right-sided temporal hemianopsia. Conclusion: Inferior chiasmatic syndrome is characterized by bitemporal hemianopsia, a deterioration of visual acuity, bilateral bow-tie descendent atrophy of the optic nerve disc, and hemianopic rigidity of the pupils. Macroprolactinomas occur more frequently in men than in women. The diagnosis is often delayed, probably because the symptoms of hyperprolactinemia are less obvious in men, while women tend to present earlier due to menstrual cycle irregularities. Prolactinomas usually have a good prognosis. Effective medical treatment with dopamine agonists is available. Knowledge of the prolactinoma symptoms could help the diagnosis of compressive lesions of the optic chiasm.</p>
      </abstract>
      <kwd-group>
        <kwd>prolactinoma</kwd>
        <kwd>pituitary gland</kwd>
        <kwd>bitemporal hemianopsia</kwd>
        <kwd>hyperprolactinemia</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R3072">
        <mixed-citation>Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290.</mixed-citation>
      </ref>
      <ref id="R3073">
        <mixed-citation>Shimon I. Giant Prolactinomas. Neuroendocrinology. 2019;109:51-</mixed-citation>
      </ref>
      <ref id="R3074">
        <mixed-citation>Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170:213-217.</mixed-citation>
      </ref>
      <ref id="R3075">
        <mixed-citation>Salmon JF. Kanski’s Clinical Ophthalmology, 9th edition. Londýn: Elsevier 2020;787-790. ISBN: 978-0-7020-7711-1.</mixed-citation>
      </ref>
      <ref id="R3076">
        <mixed-citation>Otradovec J. Klinická neurooftalmologie. Praha: Grada; 2003;205-</mixed-citation>
      </ref>
      <ref id="R3077">
        <mixed-citation>Ono M, Miki N, Kawamata T et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721-4727.</mixed-citation>
      </ref>
      <ref id="R3078">
        <mixed-citation>Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf ). 2006:265-273.</mixed-citation>
      </ref>
      <ref id="R3079">
        <mixed-citation>Kollerová J, Payer J. Štandardný diagnostický a terapeutický postup u pacienta s hyperprolaktinémiou. Ministerstvo zdravotníctva SR, schválené 1. mája 2020</mixed-citation>
      </ref>
      <ref id="R3080">
        <mixed-citation>Frisén L, Jensen C. How robust is the optic chiasm? Perimetric and neuro-imaging correlations. Acta Neurol Scand. 2008;117(3):198- 204.</mixed-citation>
      </ref>
      <ref id="R3081">
        <mixed-citation>Gedik S, Gur S, Atalay B, Colak M, Altinors N, Akova YA. Humphrey visual field analysis, visual field defects, and ophthalmic findings in patients with macro pituitary adenoma. Saudi Med J. 2007;28(9):1380-1384.</mixed-citation>
      </ref>
      <ref id="R3082">
        <mixed-citation>Ogmen BE, Ugurlu N, Faki S, Polat SB, Ersoy R, Cakir B. Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study. Int Ophthalmol. 2021;41(4):1373-1379.</mixed-citation>
      </ref>
      <ref id="R3083">
        <mixed-citation>Karl D, Gillan SN, Goudie C, Sanders R. Giant prolactinoma mimicking low-tension glaucoma at presentation. BMJ Case Rep. 2015;6.</mixed-citation>
      </ref>
      <ref id="R3084">
        <mixed-citation>Ahmed II, Feldman F, Kucharczyk W et al. Neuroradiologic screening in normal-pressure glaucoma: study results and literature review. J Glaucoma. 2002;11:279-286.</mixed-citation>
      </ref>
      <ref id="R3085">
        <mixed-citation>Česák T, Poczos P, Adamkov J et al. Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review. Pituitary. 2018;21(6):561- 570.</mixed-citation>
      </ref>
      <ref id="R3086">
        <mixed-citation>Papanastasiou L, Fountoulakis S, Pappa T et al. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene? Hormones (Athens). 2014;13(2):290- 295.</mixed-citation>
      </ref>
      <ref id="R3087">
        <mixed-citation>Inder WJ, Jang C. Treatment of Prolactinoma. Medicina (Kaunas). 2022;58(8):1095.</mixed-citation>
      </ref>
      <ref id="R3088">
        <mixed-citation>Hacisahinogullari H, Canturk S, Dogansen S, Yarman S. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas. J Fr Ophtalmol. 2022;45(5):511-518.</mixed-citation>
      </ref>
      <ref id="R3089">
        <mixed-citation>Raverot G, Jacob M, Jouanneau E et al. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol. 2009;70:588-592.</mixed-citation>
      </ref>
      <ref id="R3090">
        <mixed-citation>ISBN: 80-247-0280-0.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
